title: Response to "Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries".
abstract: A recent supplement article by Talbird, Taylor, Knoll, Frostad, and García Martí reported estimates of public health impact and cost-effectiveness of the 10-valent pneumococcal conjugate vaccine compared with the 7-valent vaccine. Although the analysis applies a decision analytic model and modeling methodologies that are scientifically sound, many of the assumptions presented in the paper are inconsistent with the current evidence.
authors.forename: David
authors.initials: D
authors.lastname: Strutton
authors.forename: Sharon
authors.initials: S
authors.lastname: Hwang
authors.forename: Raymond
authors.initials: R
authors.lastname: Farkouh
authors.forename: Craig
authors.initials: C
authors.lastname: Roberts
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000191:economics* / Q000276:immunology*
chemical_list: D022242:Pneumococcal Vaccines